)
Edge6 Feb 2026
SharkNinja: Viral by Design
How SharkNinja built a repeatable growth engine, turning overlooked appliance categories into global brands through consumer insight and iteration.
CorMedix
CorMedix (CRMD) investor relations material
CorMedix Investor Day 2026 summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Investor Day 2026 summary10 Feb, 2026
Strategic direction and business transformation
Transitioned from a single-product, renal-focused company to a diversified specialty pharmaceutical platform with multiple commercial-stage drugs and a robust pipeline, following the Melinta acquisition and integration of new leadership roles.
Completed acquisition of Melinta Therapeutics, expanding the portfolio with synergistic acute care assets and driving 2025 pro forma revenue above $400 million.
Focused on organic growth, new indications, and leveraging a dynamic institutional platform for future expansion.
Provided 2026 EBITDA guidance of $100–$125 million and initiated a $75 million share repurchase program, reflecting confidence in undervalued equity.
Positioned for continued value creation through strategic business development and financial flexibility.
Financial guidance and performance
FY 2025 pro forma net revenue exceeded $400 million, with DefenCath contributing nearly $260 million during its peak TDAPA period.
FY 2026 revenue guidance is $300–320 million, with adjusted EBITDA expected at $100–125 million.
FY 2026 DefenCath sales projected at $100–140 million, rebounding in 2027 with increased add-on payments and demand.
Maintains a strong financial position with approximately zero net debt and $148–$150 million in cash and short-term investments at year-end 2025.
$75 million share repurchase program initiated, supported by strong cash flow.
Pipeline and commercial portfolio updates
Portfolio includes a range of injectable, institutionally administered anti-infectives, with expansion focused on care settings rather than specific therapeutic areas.
REZZAYO (rezafungin) launched in 2023 for candidemia/invasive candidiasis, targeting a $250–350 million market.
Ongoing Phase 3 RESPECT study for REZZAYO prophylaxis in allogeneic BMT patients, with data expected in Q2 2026 and a >$2 billion addressable market.
DefenCath is being advanced into the TPN space, targeting prevention of CLABSI in high-risk patients, supported by the ongoing Nutriguard phase III trial and targeting a $500–$750 million market.
Multiple late-stage and preclinical programs in pipeline, including expansion into prophylaxis and pediatric hemodialysis.
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next CorMedix earnings date
Leerink Global Healthcare Conference 202610 Mar, 2026
CorMedix
Next CorMedix earnings date
Leerink Global Healthcare Conference 202610 Mar, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of infections and other complications associated with the use of catheters in dialysis and other medical settings. The company's lead product, Defencath, is an anti-infective solution designed to reduce the risk of catheter-related bloodstream infections. CorMedix is dedicated to addressing unmet medical needs in infection prevention and enhancing patient care. The company is headquartered in Berkeley Heights, New Jersey, and its shares are listed on the NASDAQ.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage